Experience with a totally implantable venous access device (Port-A-Cath®) in patients with AIDSVAN DER PIJL, H; FRISSEN, P. H. J.AIDS (London). 1992, Vol 6, Num 7, pp 709-713, issn 0269-9370Article

Myocarditis associated with reovirus infectionTERHEGGEN, F; BENEDIKZ, E; FRISSEN, P. H. J et al.European journal of clinical microbiology & infectious diseases (Print). 2003, Vol 22, Num 3, pp 197-198, issn 0934-9723, 2 p.Article

HIV-related thrombotic thrombocytopenic purpura : report of 2 cases and a review of the literatureDE MAN, A. M. E; SMULDERS, Y. M; ROOZENDAAL, K. J et al.Netherlands journal of medicine. 1997, Vol 51, Num 3, pp 103-109, issn 0300-2977Conference Paper

Hypovitaminosis D in immigrant women : slow to be diagnosedNELLEN, F. F. J. B; SMULDERS, Y. M; FRISSEN, P. H. J et al.BMJ. British medical journal (International ed.). 1996, Vol 312, Num 7030, pp 570-572, issn 0959-8146Article

An unusual presentation and way to diagnose hepatocellular carcinomaNOVOTNY, V. M. J; VAN DER HULST, V. P. M; VAN DER WOUW, P. A et al.Netherlands journal of medicine. 2004, Vol 62, Num 7, pp 254-256, issn 0300-2977, 3 p.Article

Cytomegalovirus (re)activation plays no role in the ocular vitritis observed after initiation of highly active antiretroviral therapyBOYRAZ-IKIZ, H. D; WITMER, J. P; FRISSEN, P. H. J et al.AIDS (London). 1999, Vol 13, Num 7, issn 0269-9370, p. 867Article

Renal tubular acidosis : Pathophysiology and diagnosisSMULDERS, Y. M; FRISSEN, P. H. J; SLAATS, E. H et al.Archives of internal medicine (1960). 1996, Vol 156, Num 15, pp 1629-1636, issn 0003-9926Article

Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppressionHOOGEWERF, M; REGEZ, R. M; SCHOUTEN, W. E. M et al.Lancet (British edition). 2003, Vol 362, Num 9400, pp 1979-1980, issn 0140-6736, 2 p.Article

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyREIJERS, M. H. E; WEVERLING, G. J; SCHUITEMAKER, H et al.Lancet (British edition). 1998, Vol 352, Num 9123, pp 185-190, issn 0140-6736Article

Cotrimoxazole is effective as primary prophylaxis for toxoplasmic encephalitis in HIV-infected patients : A case control studyWEIGEL, H. M; DE VRIES, E; REGEZ, R. M et al.Scandinavian journal of infectious diseases. 1997, Vol 29, Num 5, pp 499-502, issn 0036-5548Article

Zidovudine plus interferon-α versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell countz > 150 × 10⁶/I : results of the Zidon trialFERNANDEZ-CRUZ, E; LANG, J.-M; FRISSEN, P. H. J et al.AIDS (London). 1995, Vol 9, Num 9, pp 1025-1035, issn 0269-9370Article

Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected personsBRUISTEN, S. M; FRISSEN, P. H. J; KOOT, M et al.AIDS research and human retroviruses. 1997, Vol 13, Num 4, pp 327-335, issn 0889-2229Article

Herpes zoster, immunological deterioration and disease progression in HIV-1 infectionVEENSTRA, J; KROL, A; VAN PRAAG, R. M. E et al.AIDS (London). 1995, Vol 9, Num 10, pp 1153-1158, issn 0269-9370Article

Zidovudine and interferon-α combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infectionFRISSEN, P. H. J; VAN DER ENDE, M; HAVERKAMP, G et al.The Journal of infectious diseases. 1994, Vol 169, Num 6, pp 1351-1355, issn 0022-1899Article

Evaluation of the rapid immunoassay determine HIV 1/2 for detection of antibodies to human immunodeficiency virus types 1 and 2VAN DEN BERK, G. E. L; FRISSEN, P. H. J; REGEZ, R. M et al.Journal of clinical microbiology (Print). 2003, Vol 41, Num 8, pp 3868-3869, issn 0095-1137, 2 p.Article

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapyHOETELMANS, R. M. W; REIJERS, M. H. E; SCHUITEMAKER, H et al.AIDS (London). 1998, Vol 12, Num 11, pp F111-F115, issn 0269-9370Article

High-dose interferon-α2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcomaFRISSEN, P. H. J; DE WOLF, F; REISS, P et al.The Journal of infectious diseases. 1997, Vol 176, Num 3, pp 811-814, issn 0022-1899Article

Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infectionFRISSEN, P. H. J; WEVERLING, G. J; ENDERT, E et al.Journal of acquired immune deficiency syndromes and human retrovirology. 1996, Vol 12, Num 5, pp 482-488, issn 1077-9450Article

Longitudinal study on the quality of life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-αDE BOER, J. B; VAN DAM, F. S. A. M; SPRANGERS, M. A. G et al.AIDS (London). 1993, Vol 7, Num 7, pp 947-953, issn 0269-9370Article